CARDIOME PHARMA CORP (CRME) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $9.50. H.C. Wainwright advised their investors in a research report released on Jun 1, 2016.
On the company’s financial health, CARDIOME PHARMA CORP reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on May 13, 2016. Analyst had a consensus of $-0.21. The company had revenue of $7.09 million for the quarter, compared to analysts expectations of $6.22 million. The company’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.23 EPS.
CARDIOME PHARMA CORP opened for trading at $4.701 and hit $4.82 on the upside on Friday, eventually ending the session at $4.82, with a gain of 1.69% or 0.08 points. The heightened volatility saw the trading volume jump to 11,336 shares. Company has a market cap of $98 M.
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed in-hospital cardiology products BRINAVESSTM and AGGRASTAT which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)) is approved in the European Union and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.